Company Description
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines.
It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and Relation Therapeutics, using their Lab in the Loop platform to discover novel targets for osteoarthritis, systemic sclerosis and other fibrotic mechanisms, supporting our data-tech driven approach in respiratory, immunology and inflammation; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson’s disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines.
The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
| Country | United Kingdom |
| Founded | 1715 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 68,629 |
| CEO | Emma Walmsley |
Contact Details
Address: 79 New Oxford Street England, WC1A 1DG United Kingdom | |
| Phone | 44 20 8047 5000 |
| Website | gsk.com |
Stock Details
| Ticker Symbol | GSK |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| CIK Code | 0001131399 |
| CUSIP Number | 37733W204 |
| ISIN Number | US37733W2044 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sally Jackson | Senior Vice President of Global Communications and Chief Executive Officer Office |
| Emma Natasha Walmsley | Chief Executive Officer and Director |
| Julie Belita Brown A.C.A. | Chief Financial Officer and Executive Director |
| Shobie Ramakrishnan | Chief Digital and Technology Officer |
| Tony Wood | Chief Scientific Officer and Head of Research & Development |
| Nick Stone | SVice President and Head of Investor Relations |
| James Ford | Senior Vice President and Group General Counsel of Legal & Compliance |
| David Simon Redfern BSc (Hons), CA | President of Corporate Development |
| Diana Conrad | Chief People Officer |
| Philip C. Thomson | President of Global Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2025 | 6-K | Report of foreign issuer |
| Mar 3, 2025 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Mar 3, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 3, 2025 | 6-K | Report of foreign issuer |
| Mar 3, 2025 | 6-K | Report of foreign issuer |
| Mar 3, 2025 | 6-K | Report of foreign issuer |
| Mar 3, 2025 | 6-K | Report of foreign issuer |
| Feb 28, 2025 | 6-K | Report of foreign issuer |
| Feb 27, 2025 | 6-K | Report of foreign issuer |
| Feb 27, 2025 | 6-K | Report of foreign issuer |